All questionsPharmacology: Rinvoq (upadacitinib) in rheumatoid arthritis4 questions · 2 sourcesComponentsWhat are the inactive ingredients in RINVOQ 15 mg tablets?“RINVOQ 15 mg extended-release tablets for oral administration are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, ferrosoferric oxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide.” (opens the source at this quote in a new tab)CopyFlagMechanismHow does RINVOQ work (mechanism of action)?“By inactivating JAK, RINVOQ is thought to block the recruitment, phosphorylation, and activation of STATs, preventing the pro-inflammatory cytokine signal from reaching the nucleus and inhibiting pro-inflammatory processes associated with the JAK-STAT pathway.1,8,9 Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency at JAK1 and JAK2 vs JAK3 and TYK2.1 The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.” (opens the source at this quote in a new tab)CopyFlagPharmacokineticsHow is RINVOQ metabolized?“Upadacitinib metabolism is mediated by mainly CYP3A4 with a potential minor contribution from CYP2D6. The pharmacologic activity of upadacitinib is attributed to the parent molecule. In a human radiolabeled study, unchanged upadacitinib accounted for 79% of the total radioactivity in plasma while the main metabolite detected (product of monooxidation followed by glucuronidation) accounted for 13% of the total plasma radioactivity. No active metabolites have been identified for upadacitinib.” (opens the source at this quote in a new tab)CopyFlagWhat is the half-life of RINVOQ?“Upadacitinib mean terminal elimination half-life ranged from 8 to 14 hours.” (opens the source at this quote in a new tab)CopyFlag